Home Cart 0 Sign in  
X

[ CAS No. 1123-40-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1123-40-6
Chemical Structure| 1123-40-6
Chemical Structure| 1123-40-6
Structure of 1123-40-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1123-40-6 ]

Related Doc. of [ 1123-40-6 ]

Alternatived Products of [ 1123-40-6 ]

Product Details of [ 1123-40-6 ]

CAS No. :1123-40-6 MDL No. :MFCD00006671
Formula : C7H11NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :YUJCWMGBRDBPDL-UHFFFAOYSA-N
M.W : 141.17 Pubchem ID :14292
Synonyms :

Calculated chemistry of [ 1123-40-6 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.71
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 40.51
TPSA : 46.17 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.05 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.18
Log Po/w (XLOGP3) : 0.15
Log Po/w (WLOGP) : 0.07
Log Po/w (MLOGP) : 0.65
Log Po/w (SILICOS-IT) : 1.32
Consensus Log Po/w : 0.67

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.81
Solubility : 21.9 mg/ml ; 0.155 mol/l
Class : Very soluble
Log S (Ali) : -0.68
Solubility : 29.7 mg/ml ; 0.211 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.83
Solubility : 2.07 mg/ml ; 0.0147 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 1123-40-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H317-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1123-40-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1123-40-6 ]
  • Downstream synthetic route of [ 1123-40-6 ]

[ 1123-40-6 ] Synthesis Path-Upstream   1~15

  • 1
  • [ 4160-82-1 ]
  • [ 1123-40-6 ]
Reference: [1] Chemical Communications, 2013, vol. 49, # 57, p. 6331 - 6333
[2] Chemical Communications, 2013, vol. 49, # 56, p. 6331 - 6333
  • 2
  • [ 38597-82-9 ]
  • [ 1123-40-6 ]
Reference: [1] Polish Journal of Chemistry, 1980, vol. 54, # 7/8, p. 1459 - 1463
[2] Polish Journal of Chemistry, 1980, vol. 54, # 7/8, p. 1459 - 1463
  • 3
  • [ 854704-89-5 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, 1911, vol. 99, # 431, p. 432,433,434
  • 4
  • [ 77406-71-4 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, 1899, vol. 75, p. 54[2] Journal of the Chemical Society, 1901, vol. 79, p. 753
  • 5
  • [ 274690-12-9 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, 1899, vol. 75, p. 54[2] Journal of the Chemical Society, 1901, vol. 79, p. 753
  • 6
  • [ 6630-38-2 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, 1911, vol. 99, # 431, p. 432,433,434
  • 7
  • [ 4160-82-1 ]
  • [ 77287-34-4 ]
  • [ 1123-40-6 ]
Reference: [1] Yakugaku Zasshi, 1957, vol. 77, p. 118[2] Chem.Abstr., 1957, p. 8748
  • 8
  • [ 4160-82-1 ]
  • [ 57-13-6 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the American Pharmaceutical Association (1912-1977), 1950, vol. 39, p. 451,453
  • 9
  • [ 6630-38-2 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, 1911, vol. 99, p. 440
  • 10
  • [ 4839-46-7 ]
  • [ 77287-34-4 ]
  • [ 1123-40-6 ]
Reference: [1] Yakugaku Zasshi, 1957, vol. 77, p. 118[2] Chem.Abstr., 1957, p. 8748
  • 11
  • [ 66393-63-3 ]
  • [ 1123-40-6 ]
Reference: [1] Journal of the Chemical Society, Chemical Communications, 1981, # 18, p. 955 - 956
  • 12
  • [ 1123-40-6 ]
  • [ 38646-68-3 ]
YieldReaction ConditionsOperation in experiment
85%
Stage #1: With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; Heating / reflux
Stage #2: With sodium hydroxide; water In tetrahydrofuran
Stage #3: With hydrogenchloride In diethyl ether for 0.00833333 h;
Preparation of 4,4-dimethylpiperidine; A 500 mL round bottomed flask was charged with solid lithium aluminum hydride (2.5 g, 64 mmol) under an argon atmosphere, 40 mL of anhydrous tetrahydrofuran was added slowly. The suspension was cooled to O0C, then added a solution of 3,3- dimethylglutarimide (3.0 g, 21 mmol) in 20 mL anhydrous tetrahydrofuran slowly.Evolution of gas was observed. After complete addition the ice bath was removed and allowed to warm to ambient temperature. The flask was equipped with a condenser and placed in an oil bath and heated at reflux for 3 h. The solution was cooled to ambient temperature, placed flask in a bath of cool water for heat sink, then successive dropwise addition of 2.5 mL water, 2.5 mL of 15percent aq. sodium hydroxide, and 7.5 mL of water resulted in a thick suspension. Added 150 mL dry Et2U, stirred, then filtered off solids. Separated layers, dried organics with sodium sulfate and filtered. Cooled the organic solution in an ice bath and bubbled anhydrous hydrogen chloride (g) for -30 seconds. A thick white precipitate quickly forms. The solid was filtered off to yield title compound as hydrochloride salt. (2.68 g, 85percent) APCI+; 114.1.
Reference: [1] Chemical and Pharmaceutical Bulletin, 1993, vol. 41, # 11, p. 1971 - 1986
[2] Patent: WO2008/84300, 2008, A1, . Location in patent: Page/Page column 57
  • 13
  • [ 1123-40-6 ]
  • [ 81461-73-6 ]
  • [ 83928-76-1 ]
Reference: [1] Archiv der Pharmazie, 1992, vol. 325, # 5, p. 313 - 315
  • 14
  • [ 1123-40-6 ]
  • [ 83928-76-1 ]
Reference: [1] Heterocycles, 1993, vol. 36, # 7, p. 1463 - 1470
  • 15
  • [ 110-52-1 ]
  • [ 1123-40-6 ]
  • [ 20980-22-7 ]
  • [ 83928-76-1 ]
Reference: [1] Archiv der Pharmazie, 1992, vol. 325, # 5, p. 313 - 315
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 1123-40-6 ]

Gepirone Intermediates

Chemical Structure| 20980-22-7

[ 20980-22-7 ]

2-(Piperazin-1-yl)pyrimidine

Related Functional Groups of
[ 1123-40-6 ]

Amides

Chemical Structure| 1075-89-4

[ 1075-89-4 ]

8-Azaspiro[4.5]decane-7,9-dione

Similarity: 0.97

Chemical Structure| 4720-64-3

[ 4720-64-3 ]

4-Methylpiperidin-2-one

Similarity: 0.93

Chemical Structure| 561314-57-6

[ 561314-57-6 ]

2,8-Diazaspiro[4.5]decan-3-one

Similarity: 0.91

Chemical Structure| 29553-51-3

[ 29553-51-3 ]

3-Methylpiperidine-2,6-dione

Similarity: 0.91

Chemical Structure| 3298-16-6

[ 3298-16-6 ]

5-Methylpiperidin-2-one

Similarity: 0.90

Related Parent Nucleus of
[ 1123-40-6 ]

Aliphatic Heterocycles

Chemical Structure| 1075-89-4

[ 1075-89-4 ]

8-Azaspiro[4.5]decane-7,9-dione

Similarity: 0.97

Chemical Structure| 561314-57-6

[ 561314-57-6 ]

2,8-Diazaspiro[4.5]decan-3-one

Similarity: 0.91

Chemical Structure| 29553-51-3

[ 29553-51-3 ]

3-Methylpiperidine-2,6-dione

Similarity: 0.91

Chemical Structure| 3298-16-6

[ 3298-16-6 ]

5-Methylpiperidin-2-one

Similarity: 0.90

Chemical Structure| 1121-89-7

[ 1121-89-7 ]

Piperidine-2,6-dione

Similarity: 0.90

Piperidines

Chemical Structure| 1075-89-4

[ 1075-89-4 ]

8-Azaspiro[4.5]decane-7,9-dione

Similarity: 0.97

Chemical Structure| 4720-64-3

[ 4720-64-3 ]

4-Methylpiperidin-2-one

Similarity: 0.93

Chemical Structure| 561314-57-6

[ 561314-57-6 ]

2,8-Diazaspiro[4.5]decan-3-one

Similarity: 0.91

Chemical Structure| 29553-51-3

[ 29553-51-3 ]

3-Methylpiperidine-2,6-dione

Similarity: 0.91

Chemical Structure| 3298-16-6

[ 3298-16-6 ]

5-Methylpiperidin-2-one

Similarity: 0.90